Tumor Biology

, Volume 36, Issue 6, pp 4773–4776 | Cite as

High serum microRNA-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients

Research Article


Previous studies have shown that some microRNAs (miRs) are intensively involved in the development of hepatocellular carcinoma. We analyzed the prognostic role of serum microRNA (miR-122) levels in hepatocellular carcinoma patients using a retrospective design. MiR-122 levels in 122 hepatocellular carcinoma patients were measured, and Cox regression analysis was performed to analyze the prognostic role of miR-122 in hepatocellular carcinoma, and the hazard ratio (HR) with 95 % confidence interval (95 %CI) was used to evaluate its prognostic role. Patients with large tumor size had lower levels of serum miR-122 (P = 0.04). However, there was no significant association of serum miR-122 levels with other clinical characteristics. Kaplan-Meier method showed that there was higher overall survival rate in hepatocellular carcinoma patients with high serum miR-122 levels compared with those with low miR-122 level (P < 0.01). When using Cox regression analysis, high serum miR-122 level was independently associated with better overall survival in hepatocellular carcinoma patients (HR = 0.26; 95 %CI 0.14–0.47, P < 0.01). Subgroup analysis by gender showed that high serum miR-122 level was independently associated with better overall survival in male patients (HR = 0.08; 95 %CI 0.03–0.22, P < 0.01), but not in female patients (HR = 0.48; 95 %CI 0.18–1.32, P = 0.16). Thus, the outcomes in the analysis suggest that high serum miR-122 level is independently associated with higher overall survival rate in hepatocellular carcinoma patients, and it is a good biomarker of better prognosis in patients with hepatocellular carcinoma.


Hepatocellular carcinoma miR-122 Overall survival 


Conflicts of interest



  1. 1.
    Lafaro KJ, Demirjian AN, Pawlik TM. Epidemiology of hepatocellular carcinoma. Surg Oncol Clin N Am. 2015;24:1–17.CrossRefPubMedGoogle Scholar
  2. 2.
    El-Serag HB, Kanwal F. Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology. 2014;60:1767–75.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol. 2014;28:753–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Hoshida Y, Fuchs BC, Bardeesy N, Baumert TF, Chung RT. Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol. 2014;61:S79–90.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Nault JC. Pathogenesis of hepatocellular carcinoma according to aetiology. Best Pract Res Clin Gastroenterol. 2014;28:937–47.CrossRefPubMedGoogle Scholar
  6. 6.
    Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901–10.CrossRefPubMedGoogle Scholar
  7. 7.
    Walker JJ, Johnson JA, Wild SH. Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure. Lancet Diabetes Endocrinol. 2013;1:132–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Scheen AJ, Van Gaal LF. Combating the dual burden: therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol. 2014;2:911–22.CrossRefPubMedGoogle Scholar
  9. 9.
    Bolland MJ, Grey A, Gamble GD, Reid IR. The effect of vitamin d supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis. Lancet Diabetes Endocrinol. 2014;2:307–20.CrossRefPubMedGoogle Scholar
  10. 10.
    Rich N, Singal AG. Hepatocellular carcinoma tumour markers: current role and expectations. Best Pract Res Clin Gastroenterol. 2014;28:843–53.CrossRefPubMedGoogle Scholar
  11. 11.
    Shenoy A, Blelloch RH. Regulation of microRNA function in somatic stem cell proliferation and differentiation. Nat Rev Mol Cell Biol. 2014;15:565–76.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15:509–24.CrossRefPubMedGoogle Scholar
  13. 13.
    Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20:460–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Jasinski-Bergner S, Mandelboim O, Seliger B. The role of microRNAs in the control of innate immune response in cancer. J Natl Cancer Inst. 2014;106.Google Scholar
  15. 15.
    Zhu Z, Zhang X, Wang G, Zheng H. Role of microRNAs in hepatocellular carcinoma. Hepat Mon. 2014;14:e18672.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic silencing of microrna-122 in primates with chronic hepatitis C virus infection. Science. 2010;327:198–201.CrossRefPubMedGoogle Scholar
  17. 17.
    Jopling C. Liver-specific microRNA-122: biogenesis and function. RNA Biol. 2012;9:137–42.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Waidmann O, Koberle V, Brunner F, Zeuzem S, Piiper A, Kronenberger B. Serum microRNA-122 predicts survival in patients with liver cirrhosis. PLoS One. 2012;7:e45652.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Xu J, Zhu X, Wu L, Yang R, Yang Z, Wang Q, et al. Microrna-122 suppresses cell proliferation and induces cell apoptosis in hepatocellular carcinoma by directly targeting wnt/beta-catenin pathway. Liver Int. 2012;32:752–60.CrossRefPubMedGoogle Scholar
  20. 20.
    Tsai WC, Hsu SD, Hsu CS, Lai TC, Chen SJ, Shen R, et al. Microrna-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. J Clin Invest. 2012;122:2884–97.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum microRNAs as biomarkers for hepatocellular carcinoma in Chinese patients with chronic hepatitis B virus infection. PLoS One. 2011;6:e28486.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Thibault PA, Huys A, Dhillon P, Wilson JA. Microrna-122-dependent and -independent replication of hepatitis c virus in hep3b human hepatoma cells. Virology. 2013;436:179–90.CrossRefPubMedGoogle Scholar
  23. 23.
    Gupta P, Cairns MJ, Saksena NK. Regulation of gene expression by microRNA in HCV infection and HCV-mediated hepatocellular carcinoma. Virol J. 2014;11:64.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Li C, Wang Y, Wang S, Wu B, Hao J, Fan H, et al. Hepatitis b virus mRNA-mediated mir-122 inhibition upregulates pttg1-binding protein, which promotes hepatocellular carcinoma tumor growth and cell invasion. J Virol. 2013;87:2193–205.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Koberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, et al. Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma. Eur J Cancer. 2013;49:3442–9.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Yongqing Xu
    • 1
  • Xianmin Bu
    • 1
  • Chaoliu Dai
    • 1
  • Chao Shang
    • 2
  1. 1.Department of Hepatobiliary and Spleen SurgeryShengjing Hospital of China Medical UniversityShenyangChina
  2. 2.Department of Neural BiologyBasic Medical College of China Medical UniversityShenyangChina

Personalised recommendations